Nimbus Therapeutics announced the launch of a first-in-human clinical trial for NDI-219216, its investigational Werner ...

Enhertu (trastuzumab deruxtecan), in combination with pertuzumab, shows promise as a new first-line treatment for ...

In the phase 3 HARMONi-6 trial, ivonescimab, Akeso’s PD-1/VEGF bispecific antibody, combined with chemotherapy, demonstrated ...

Boehringer Ingelheim has announced a collaboration with Tessellate Bio, to develop a new class of targeted therapies for ...

The Phase 3 ASCENT-04 clinical trial has demonstrated that combining the antibody-drug conjugate Trodelvy® with the ...

Biosciences announced the first patient has been dosed in its Phase 2 trial of MB-105, a first-in-class CD5-targeted CAR-T ...

Medicus Pharma’s Phase 2 trial of its dissolvable microneedle patch for nodular basal cell carcinoma has expanded from 60 to 90 patients, with new sites added in the U.S. and Europe. Backed by over 60 ...

Bayer Pharmaceuticals announced a landmark year for 2025, showcasing major advancements in its drug development pipeline and ...

We are pleased to present an exclusive interview with Dana Brown, CEO and Chairman of the Board at iCAD Inc., to explore the future of breast cancer screening and the role of artificial intelligence ...